$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Genetic therapy for transplant vascular sclerosis

Transplant immunology, v.5 no.4, 1997년, pp.299 - 302  

Bennett, C Frank (Address for correspondence: CF Bennett, Isis Pharmaceuticals Inc., 2280 Faraday Ave, Carlsbad, CA 92009, USA.) ,  Stepkowski, Stanislaw M (Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School at Houston, Houston, Texas U.S.A.)

초록이 없습니다.

참고문헌 (50)

  1. J Heart Lung Transplant Hosenpud 11 9 1992 Cardiac allograft vasculopathy: current concepts, recent developments, and future directions 

  2. Transplantation Paul 53 1169 1992 10.1097/00007890-199206000-00001 Chronic vascular rejection of the heart and the kidney - have rational treatment options emerged? 

  3. Clin Transplantation Orosz 10 100 1996 Local cellular immunology of experimental transplant vascular sclerosis 

  4. Science Ohno 265 781 1994 10.1126/science.8047883 Gene therapy for vascular smooth muscle cell proliferation after arterial injury 

  5. Science Lau 273 109 1996 10.1126/science.273.5271.109 Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice 

  6. Ann Rev Biochem Green 55 569 1986 10.1146/annurev.bi.55.070186.003033 The Role of Antisense RNA in Gene Regulation 

  7. Sci. Am Weintraub 262 40 1990 10.1038/scientificamerican0190-40 Antisense RNA and DNA 

  8. Proc Nat Acad Sci USA Iyer 93 9960 1996 10.1073/pnas.93.18.9960 Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense 

  9. Sci Am Cech 255 64 1986 10.1038/scientificamerican1186-64 RNA as an enzyme 

  10. Science Stein 261 1004 1993 10.1126/science.8351515 Antisense oligonucleotides as therapeutic agents - is the bullet really magical? 

  11. Ann Rev Pharmacol Toxicol Crooke 36 107 1996 10.1146/annurev.pa.36.040196.000543 Progress in antisense oligonucleotide therapeutics 

  12. Curr Opin Struct Biol Cech 2 605 1992 10.1016/0959-440X(92)90093-M Ribozyme engineering 

  13. J Mol Biol Sioud 224 831 1992 10.1016/0022-2836(92)90244-E Performed ribozyme destroys tumour necrosis factor mRNA in human cells 

  14. Curr Opin Struct Biol Sun 3 345 1993 10.1016/S0959-440X(05)80105-8 Oligonucleotide-directed triple-helix formation 

  15. Science Bielinska 250 997 1990 10.1126/science.2237444 Regulation of gene expression with double-stranded phosphorothioate oligonucleotides 

  16. J Immunol Stepkowski 153 5336 1994 10.4049/jimmunol.153.11.5336 Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities 

  17. Proc Nat Acad Sci USA Morishita 90 8474 1993 10.1073/pnas.90.18.8474 Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia 

  18. Proc Nat Acad Sci USA Mann 92 4502 1995 10.1073/pnas.92.10.4502 Genetic engineering of vein grafts resistant to atherosclerosis 

  19. Proc Nat Acad Sci USA Morishita 92 5855 1995 10.1073/pnas.92.13.5855 A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo 

  20. J Clin Invest Mann 99 1295 1997 10.1172/JCI119288 Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts 

  21. J Immunol Bennett 152 3530 1994 10.4049/jimmunol.152.7.3530 Inhibition of endothelial cell-leucocyte adhesion molecule expression with antisense oligonucleotides 

  22. Adv Pharmacol Bennett 28 1 1994 10.1016/S1054-3589(08)60492-5 Regulation of endothelial cell adhesion molecule expression with antisense oligonucleotides 

  23. Ann Rev Pharmacol Toxicol Crooke 32 329 1992 10.1146/annurev.pa.32.040192.001553 Therapeutic applications of oligonucleotides 

  24. Nature Wagner 372 333 1994 10.1038/372333a0 Gene inhibition using antisense oligodeoxynucleotides 

  25. Crooke 1995 

  26. TIBTECH Stein 14 147 1996 10.1016/0167-7799(96)20006-X Phosphorothioate antisense oligodeoxynucleotides: questions of specificity 

  27. J Biol Chem Chiang 266 18162 1991 10.1016/S0021-9258(18)55250-9 Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms 

  28. Exp Cell Res Miele 214 231 1994 10.1006/excr.1994.1253 Enhanced metastatic ability of TNF-α-treated malignant melanoma cells is reduced by initercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides 

  29. J Invest Dermatol Nestle 103 569 1994 10.1111/1523-1747.ep12396876 Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes 

  30. J Clin Invest Yan 91 986 1993 10.1172/JCI116320 Human/severe combined immunodeficient mouse chimeras: an experimental in vivo model system to study the regulation of human endothelial cell-leucocyte adhesion molecules 

  31. Proc Nat Acad Sci USA Murray 91 9146 1994 10.1073/pnas.91.19.9146 Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse 

  32. Am J Pathol Christofidou-Solomidou 150 631 1997 Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras 

  33. Science Isobe 255 1125 1992 10.1126/science.1347662 Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1 

  34. Transplant Proc Katz 27 3214 1995 Efficacy of ICAM-1 antisense oligonucleotide in pancreatic islet transplantation 

  35. J Clin Invest Kumasaka 97 2362 1996 10.1172/JCI118679 The role of the Intercellular Adhesion Molecule-1 (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice 

  36. J Pharmacol Exp Ther Bennett 280 988 1997 An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice 

  37. Kidney Int Haller 50 473 1996 10.1038/ki.1996.338 Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat 

  38. Toxicol Henry 120 1450 1997 10.1016/S0300-483X(97)03661-5 Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide: 2) 4-week study in cynomolgus monkeys 

  39. Antisense Nuc Drug Dev Henry 7 473 1997 10.1089/oli.1.1997.7.473 Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide, following repeated intravenous administration: 1) 4-week study in CD-1 mice 

  40. Proc Nat Acad Sci USA Sligh 90 8529 1993 10.1073/pnas.90.18.8529 Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1 

  41. J Exp Med Xu 180 95 1994 10.1084/jem.180.1.95 Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice 

  42. Levin 1997 Toxicity of oligodeoxynucleotide therapeutic agents 

  43. Anti-Cancer Drug Design Monteith 1997 Immune stimulation-A class effect of phosphorothioate oligonucleotides in rodents 

  44. J Pharmacol Exp Therap Glover 252 1173 1997 Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302) 

  45. Gastroenterology Yacyshyn 112 A1123 1997 Efficacy and safety of ISIS 2302 (ICAM-1 antisense oligonucleotide) treatment of steroid-dependent Crohn's disease 

  46. Biochem Pharmacol Zhao 51 173 1995 10.1016/0006-2952(95)02177-9 Effect of different chemically modified oligodeoxynucleotides on immune stimulation 

  47. J Pharmacol Exp Therap Crooke 277 923 1996 Pharmacokinetic properties of several novel oligonucleotide analogs in mice 

  48. J Pharmacol Exp Ther Zhang 278 971 1996 Pharmacokinetics and tissue distribution of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration 

  49. J Biol Chem Baker 272 11994 1997 10.1074/jbc.272.18.11994 2′-O-(2-methoxy)ethyl modified anti-ICAM-1 oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in HUVECs 

  50. Antisense Nuc Acid Drugs Dev Boggs 7 461 1997 10.1089/oli.1.1997.7.461 Characterization and modulation of immune stimulation by modified oligonucleotides 

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로